Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Zelebrudomide · NX-2127

Small molecule (Molecular glue degrader) · Degrader of Bruton's tyrosine kinase (BTK) · developed by Nurix Therapeutics

Phase 1 Most advanced trial
NRIX Developer
1 Registered trials

What is Zelebrudomide?

Zelebrudomide is an orally bioavailable chimeric targeting molecule that links a cereblon-binding moiety to a BTK-binding moiety. It recruits the CRL4-CRBN E3 ubiquitin ligase to BTK, driving its ubiquitination and proteasomal degradation, and also degrades the CRBN neosubstrates Aiolos and Ikaros. It is being studied in B-cell lymphomas and chronic lymphocytic leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NX-2127
Drug type
Small molecule (Molecular glue degrader)
Targets
Bruton's tyrosine kinase (BTK), cereblon (CRBN) (binding partner it blocks), Aiolos (IKZF3) (secondary target), Ikaros (IKZF1) (secondary target)
Mechanism
Degrader of Bruton's tyrosine kinase (BTK)
Pathways
B-cell receptor signaling, CRL4-CRBN E3 ubiquitin ligase-mediated ubiquitination and proteasomal degradatio, T-cell activation
Therapy area
Oncology
Developer
Nurix Therapeutics, Inc. (NRIX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
C9V5FHZ2L3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04830137 Phase 1 Chronic Lymphocytic Leukemia (CLL) Recruiting NRIX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Lymphocytic Leukemia (CLL)Diffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Marginal Zone Lymphoma (MZL)Primary Central Nervous System Lymphoma (PCNSL)Small Lymphocytic Lymphoma (SLL)Waldenstrom Macroglobulinemia (WM)

Other drugs acting on BTK

More from Nurix Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NRIX page.

Follow NRIX, the company behind Zelebrudomide

See NRIX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NRIX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.